Does a lung cancer drug lower or raise other health risks?

Researchers tracked how often a drug called bevacizumab improved survival without causing new lung damage in people fighting the most common type of lung cancer that starts outside the lungs. The study looked at adults who had never been treated for this cancer but were about to start a standard first-line chemotherapy with platinum-based drugs. Half a year after treatment began, the data showed a surprising detail: patients on bevacizumab had fewer episodes of a rare but serious lung condition called interstitial lung disease. At the same time, the drug did not make a clear difference in how long these patients lived or in how often they developed dangerous blood clots in the legs or lungs.Doctors already knew bevacizumab can help shrink tumours in some cases, but this large national study adds a fresh layer: it seems the drug may protect fragile lung tissue from further harm while the immune system fights the cancer. Still, the findings don’t prove that every patient should take bevacizumab. Each person’s immune system, tumour type, and overall health can swing the balance in different directions.